Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study

Clinical and Translational Gastroenterology

Volumn 8, Issue 4, 2017, Pages

  Gray, Ronan T ^a   Cantwell, Marie M ^a   Coleman, Helen G ^a   Loughrey, Maurice B ^a,b   Bankhead, Peter ^a   McQuaid, Stephen ^a   O'Neill, Roisin F ^a   Arthur, Kenneth ^a   Bingham, Victoria ^a   McGready, Claire ^a   Gavin, Anna T ^a   Cardwell, Chris R ^a   Johnston, Brian T ^b   James, Jacqueline A ^a,b   Hamilton, Peter W ^a   Salto Tellez, Manuel ^a,b   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; COLON CANCER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OVERALL SURVIVAL; PIK3CA GENE; POPULATION RESEARCH; PRIORITY JOURNAL; PTGS2 GENE; VERY ELDERLY;

EID: 85028557115     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2017.18     Document Type: Article

References (33)

1. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
2. Rothwell PM, Wilson M, Price JF et al. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
3. Bains SJ, Mahic M, Myklebust TA et al. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. J Clin Oncol 2016; 34: 2501-2508.
4. Elwood PC, Gallagher AM, Duthie GG et al. Aspirin, salicylates, and cancer. Lancet 2009; 373: 1301-1309.
5. Ogino S, Lochhead P, Giovannucci E et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014; 33: 2949-2955.
6. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival. N Engl J Med 2012; 367: 1596-1606.
7. Domingo E, Church DN, Sieber O et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013; 31: 4297-4305.
8. Ogino S, Chan AT, Fuchs CS et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60: 397-411.
9. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-659.
10. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
11. Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumor Biol 2010; 31: 623-631.
12. Uddin S, Ahmed M, Hussain A et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 2010; 126: 382-394.
13. Kothari N, Kim R, Jorissen RN et al. Impact of regular aspirin use on overall and cancerspecific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol 2015; 54: 487-492.
14. Reimers MS, Bastiaannet E, Langley RE et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 2014; 174: 732-739.
15. Cardwell CR, Kunzmann AT, Cantwell MM et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: A case-control analysis of a populationbased cohort. Gastroenterology 2014; 146: 700-708.
16. Zhang D, Salto-Tellez M, Putti TC et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003; 16: 79-84.
17. Boyle DP, McArt DG, Irwin G et al. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology 2014; 65: 340-352.
18. McCarty KS, Szabo E, Flowers JL et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46: 4244s-4248s.
19. Budczies J, Klauschen F, Sinn BV et al. Cutoff Finder: A comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE 2012; 7: e51862.
20. Fumagalli D, Gavin PG, Taniyama Y et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010; 10: 101.
21. Gavin PG, Colangelo LH, Fumagalli D et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18: 6531-6541.
22. Khan NF, Perera R, Harper S et al. Adaptation and validation of the Charlson Index for Read/ OXMIS coded databases. BMC Fam Pract 2010; 11: 1.
23. Paleari L, Puntoni M, Clavarezza M et al. PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin Oncol 2016; 28: 317-326.
24. Elwood PC, Morgan G, Pickering JE et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: A systematic review and meta-analyses of published studies. PLoS ONE 2016; 11: e0152402.
25. Lévesque LE, Hanley JA, Kezouh A et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.
26. Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA 2011; 305: 2335-2342.
27. Bos ACRK, van Erning FN, van Gestel YRBM et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 2015; 51: 2553-2561.
28. Yang Y-X, Hennessy S, Propert K et al. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2008; 17: 869-876.
29. Bedson J, Whitehurst T, Lewis M et al. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 2001; 51: 1001-1003.
30. Baade PD, Meng X, Youl PH et al. The impact of body mass index and physical activity on mortality among patients with colorectal cancer in Queensland, Australia. Cancer Epidemiol Biomarkers Prev 2011; 20: 1410-1420.
31. Haydon AMM, MacInnis RJ, English DR et al. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006; 55: 62-67.
32. Kuiper JG, Phipps AI, Neuhouser ML et al. Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control 2012; 23: 1939-1948.
33. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012; 18: 3524-3531.